Correction
21 Jul 2015: Ouyang Y, Li F, Shao Q, Heussen FM, Keane PA, et al. (2015) Correction: Subretinal Fluid in Eyes with Active Ocular Toxoplasmosis Observed Using Spectral Domain Optical Coherence Tomography. PLOS ONE 10(7): e0134074. https://doi.org/10.1371/journal.pone.0134074 View correction
Figures
Abstract
Purpose
To describe the clinical finding of subretinal fluid (SRF) in the posterior pole by spectral domain optical coherence tomography (SD-OCT) in eyes with active ocular toxoplasmosis (OT).
Methods
Eyes with active OT which underwent SD-OCT were reviewed. SRFs in the posterior pole were further analyzed.
Main Outcome Measures
Presence of SRF; its accompanying features, e.g. retinal necrosis, cystoid macular edema (CME), choroidal neovascularization (CNV); and longitudinal changes of SRF, including maximum height and total volume before and after treatment.
Results
SRF presented in 45.5% (or 15/33) of eyes with typical active OT and in 51.3% (or 20/39) of eyes with active OT. The mean maximum height and total volume of SRF were 161.0 (range: 23–478) µm and 0.47 (range: 0.005–4.12) mm3, respectively. For 12 eyes with SRF related to active retinal necrosis, SRF was observed with complete absorption after conventional anti-toxoplasmosis treatment. The mean duration for observation of SRF clearance was 33.8 (range: 7–84) days. The mean rate of SRF clearance was 0.0128 (range: 0.0002–0.0665) mm3/day.
Conclusions
SRF (i.e., serous retinal detachment) is a common feature in patients with active OT when SD-OCT is performed. The majority of SRF was associated with retinal necrosis and reacted well to conventional therapy, regardless of total fluid volume. However, SRF accompanying with CME or CNV responded less favorably or remained refractory to conventional or combined intravitreal treatment, even when the SRF was small in size.
Citation: Ouyang Y, Li F, Shao Q, Heussen FM, Keane PA, Stübiger N, et al. (2015) Subretinal Fluid in Eyes with Active Ocular Toxoplasmosis Observed Using Spectral Domain Optical Coherence Tomography. PLoS ONE 10(5): e0127683. https://doi.org/10.1371/journal.pone.0127683
Academic Editor: Pedro Gonzalez, Duke University, UNITED STATES
Received: February 7, 2015; Accepted: April 17, 2015; Published: May 26, 2015
Copyright: © 2015 Ouyang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Data Availability: Data cannot be made publicly available due to ethical restrictions protecting patient privacy. Data is available upon request at: yanlingyouyang@gmail.com, and who can provide deidentified and the Federal Data Protection Act (Bundesdatenschutzgesetz) compliant data set.
Funding: This work was supported by the funding from the Federal Ministry of Education and Research of Germany (BMBF) through the Toxonet 02 research collaboration. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: Dr. Li received funding from the Youth Research Foundation of the national health and family planning commission of Jilin Province, China. Dr. Keane has received a proportion of his funding from the Department of Health’s NIHR Biomedical Research Centre for Ophthalmology at Moorfields Eye Hospital and UCL Institute of Ophthalmology. Drs. Keane and Heussen have received travel grants from the Allergan European Retina Panel. Dr. Pleyer received funding from the federal ministry of education and research of Germany (BMBF) through the Toxonet 02 research collaboration and has been the Principal Investigator/Consultant for Abbott, Alcon, Allergan, Amgen, Bausch and Lomb, Bayer/Schering, Centocor, Esba Tech, Novartis but no commercial interests or financial relationships to any agent/device/technique. Dr. Sadda receives research support and serves as a consultant to Carl Zeiss Meditec and Optos. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.
Introduction
Ocular toxoplasmosis (OT) is the most common etiology of infectious posterior uveitis in otherwise healthy individuals, leading to legal blindness in at least one eye in approximately 25% of patients [1,2]. It is caused by Toxoplasma gondii and frequently affects children and young adults, with significant morbidity, and thus has considerable socio-economic implications. The disease characteristics vary in different areas of the world [3]. Active OT consists of well-defined foci of coagulative necrosis of the retina. Toxoplasma gondii antigens are often detected in areas of necrosis by immunohisto- chemistry. Diagnosis of OT is based on clinical characteristics consistent with toxoplasmic retinochoroiditis (foci of retinal necrosis with associated retinal inflammation), in the absence of other identifiable causes [3]. In recent years, clinically tailored laboratory analysis, including serology and/or aqueous humor analysis (detection of intraocular Toxoplasma gondii antibodies with Goldmann/Witmer coefficient >3) was also used to aid the diagnosis of OT for eyes with atypical clinical manifestations [2].
Subretinal fluid (SRF) or exudative/serous retinal detachment (RD) is commonly observed in posterior uveitis. The effect of SRF on vision and its response to therapy in uveitis patients has been an active field of interests in recent years [4]. However, the frequency and visual impact of SRF in OT have not been well defined. The early observation of SRF in patients with OT can be traced back to 1960s, when the parasite was successfully isolated from SRF [5]. Since then, SRF in OT has been mainly reported in the literature anecdotally as case reports or briefly mentioned in the case series [6–10].
Optical coherence tomography (OCT) provides high-resolution cross-sectional images of the neurosensory retina and has been proven to be useful in the management of uveitis. In patients with serous RD, OCT parameters can be a reliable real-time indicator of the severity of the inflammation and the effectiveness of the treatment. These parameters can be more reliable than the visual acuity in assessing response to intervention [11]. Widespread availability of spectral domain OCT (SD-OCT) has provided improved visualization of the details of the neurosensory retina and has facilitated the detection of many retinal/choroidal abnormalities, including cystoid lesions in OT and SRF [10, 12, 13]. The purpose of the current study is to report the observation of SRF in patients with active OT, and to investigate its associate clinical course and therapeutic consequences.
Materials and Methods
Baseline Data Collection
Data were retrospectively collected from consecutive patients attending the Department of Ophthalmology at Charité, University Berlin, between January 2010 and September 2013, with a diagnosis of OT. Only patients with typical or atypical active episodes related to OT were included. Typical active OT was defined based on the clinical picture of a characteristic newly observed focus of retinitis (example shown in Fig 1-A), which usually arises from the border of a retinochoroidal scar, in the absence of other identifiable causes [3] [14] [15], with or without laboratory confirmation. Atypical OT episode was considered in suspected cases with atypical presentation, who deemed to be positive with the clinically tailored laboratory analysis, including serology and/or aqueous humor analysis (detection of intraocular Toxoplasma gondii antibodies with Goldmann/Witmer coefficient >3) [15]; or who presented with recurrent symptoms in eyes with confirmed previous diagnosis of OT. Patients with acquired immunodeficiency syndrome (AIDS), other immune system related diseases, or individuals receiving immunosuppressive agents (other than corticosteroids specifically for OT) were excluded. For inclusion in the study, all patients with active OT were required to have undergone volume OCT scanning with spectral domain OCT (Spectralis, Heidelberg Engineering, Germany).
Parts A-D: fundus photos (FP) and OCT images on the initial visit. Part A: a fresh whitish inflammatory lesion superior to the macula in the extramacular area, with intraretinal hemorrhage and SRF surrounding the necrosis. Parts B-D: OCT B-scans corresponding to the lines B-D shown in Part A. Vitreous cells were present with normal retinal structure through the fovea (Part B). In areas surrounding the active lesion, SRF was visable (Part C-D). Full-thickness retina destruction (retinal necrosis) accompanied by largely increased choroidal thickness (744 μm) was present (Part D). Parts E-H: FP and OCT images 6 weeks after the initial visit. Part E: previous whitish inflammatory lesion was smaller without visible SRF. Parts F-H: OCT B-scans corresponding to the lines F-H shown in Part E. Absence of SRF and dramatically lessened vitreous cells in the macula and area around the active lesion were observed (Part F-H). Retina got thinner, but still with full-thickness necrosis at the previous active site (Part H). The choroid thickness decreased to 345 μm (Part H). Parts C1-C2 showed the segmentation of retinal layers in OCT B-scan corresponding to Figure C. Part C3-C5: quantitative measurement results from manual segmentation. Part C3: the color bar showing the correlation of thickness and color range. Parts C4-C5: mean retinal thickness and mean SRF height shown in early treatment diabetic retinopathy study (ETDRS) grid using foveola as the center of the grid. The correlation of numbers and subfields are as follows: 1 = superior outer macula; 2 = temporal outer macula; 3 = inferior outer macula; 4 = nasal outer macula; 5 = superior inner macula; 6 = temporal inner macula; 7 = inferior inner macula; 8 = nasal inner macula; 9 = central subfield). ILM = internal limiting membrane; PR = photoreceptor layer; RPE = retinal pigment epithelium.
Information regarding age, sex, ethnicity, history of ophthalmic diseases or surgeries, ophthalmic diagnosis, and lens status were also collected. Best-corrected visual acuity (VA) was measured using Snellen VA charts. Approval for data collection and analysis was obtained from the institutional review board of the University Göttingen ethics committee as part of the multi-center German “Toxonet” project. The research adhered to the tenets set forth in the Declaration of Helsinki. Written consent was given by the patients for their information to be stored in the hospital database and used for research.
Characteristics of eyes with activity related to OT by Clinical Observation
Eyes with active episodes related to OT were evaluated and categorized into 3 groups: 1) "typical active OT", defined as eyes with clinical characteristics of a newly observed focus of retinitis (example shown in Fig 1-A), with or without previous diagnosis of OT; 2) "new atypical active OT", defined as lesions without typical characteristics of a focus of retinitis, but confirmed by laboratory testing at the current visit; in eyes without previous diagnosis of OT; 3) "recurrent atypical active OT", defined as eyes with previous diagnosis of OT presenting with newly onset symptoms, without typical clinical manifestation or confirmatory laboratory testing at the current visit.
Clinical characteristics of active OT were first collected from dilated fundus examination and/or fundus photos (FP), or fluorescein angiography (FA) if available. Locations of these lesions were documented for both ‘zone' (as described by Holland et al. [16]) and area (as 'macula involving the fovea'; 'macula not involving the fovea'; 'extramacula within the posterior pole'). In addition, the presence or absence of choroidal neovascularization (CNV) was also noted, as determined by clinical examination and FA.
OCT Scanning Protocols and Analysis
In each case, macular volume OCT scans were obtained (i.e., image sets centered approximately on the fovea) using Spectralis OCT. If the active lesion affected areas within the posterior pole but outside the macula, including (1) nasal to the optic disc, (2) superior to the superotemporal vascular arcade, (3) inferior to the inferotemporal vascular arcade, and (4) temporal to the macula [17], then the corresponding extramacular volume OCT scans were also captured. Raw OCT data were exported from the imaging system and imported into validated custom grading software (3D-OCTOR, Doheny Image Reading Center (DIRC), Los Angeles, CA) [18] for further review.
OCT Grading Methodology
Two graders (Y.O., F.M.H.), certified for the assessment of OCT images at the DIRC, evaluated each OCT image set independently. The presence or absence of SRF was firstly assessed at baseline. When SRF was identified, the co-existence of other features was also documented, including presence or absence of total retinal layer destruction (i.e. retinal necrosis, example in Fig 1-D), cystoid macular edema (CME) (example in Fig 2), and disruption of photoreceptor layer (PR) according to a pre-existing OCT grading methodology [19,20]. The location of SRF was also graded as "macula involving the fovea", or "macula not involving the fovea" or "extramacula". For eyes with SRF at baseline, OCT sets in the follow-up visits were also assessed for presence or absence of SRF. Finally, the earliest date of the OCT scans showing SRF clearance was noted.
Parts A1, B1, C1, D1 showed characteristics of SRF and CME seen on OCT B-scans through the fovea. Parts A2, B2, C2, D2 demonstrated mean retinal thickness maps shown in early treatment diabetic retinopathy study (ETDRS) grid. Parts A3, B3, C3, D3 were maps of mean SRF height shown in ETDRS grid. SRF and CME kept relatively unchanged for the first 3 visits, and started to respond to treatment on the 4th visit. Parts E-K revealed absence of SRF in the following visits, after 3 intraocular injection of 1.25 mg bevacizumab. However, CME remained persistent, although minimization at one time point (H) was temporally seen.
A reading center open adjudication process was applied to obtain a final consensus result for each case from the dual grading process.
Quantitative Analysis of OCT Images
For OCT sets containing SRF, manual segmentation was performed, which includes delineation of: internal limiting membrane (ILM) inner boundary, PR outer boundary and retinal pigment epithelium (RPE) inner boundary (example indicated in Fig 1-C1). This segmentation allowed both quantification of retinal thickness (defined as distance between ILM inner and RPE inner boundaries) and multiple measurements of SRF (defined as PR outer to RPE inner boundaries), including maximum and minimum height, area and total volume (example shown in Fig 1-C2). Quantitative parameters were then reported based on the individual subfields or the entire area of the Early Treatment Diabetic Retinopathy Study (ETDRS) grid (example shown in Fig 1-C3, C4 and C5).
Data Analysis and Statistical Methods
Duration of observed SRF clearance was defined as days between first available OCT date with SRF (as baseline) and the earliest available OCT date showing absence of SRF in the follow-up visits. The rate of SRF clearance was calculated as the total SRF volume at baseline divided by the duration of observed SRF.
Clinical and imaging data were analyzed with frequency and descriptive statistics. Statistical analysis was performed using commercially available software SPSS (version 19.0, SPSS Inc., Chicago, Illinois, United States).
Results
Baseline Characteristics
A total of 142 patients with a diagnosis of OT were seen in our tertiary center within the study period, of which, 40 eyes from 39 patients with active episodes related to OT had undergone volume OCT scanning and were reviewed in the study. Among them, one patient was excluded due to an associated diagnosis of AIDS. As a result, 39 eyes from 38 patients were included in the study, comprising 33 eyes with typical active OT, 1 eye with new atypical active OT, and 5 eyes with recurrent atypical OT. The mean patient age was 41.2 ± 17.9 years (range, 15–78 years). Eighteen patients (47.4%) were women and 20 (52.6%) were men.
All OCT images included in the study met reading center criteria for sufficient image quality, meaning that the retinal layers could be analyzed and segmented with greater than 90% confidence.
Overall Presence of SRF
In total, 20 eyes from 20 subjects demonstrated SRF in the posterior pole that was confirmed by SD-OCT, resulting in a presence of SRF as 51.3% (or 20/39) in active OT. Among them, 15 eyes with typical active OT, 1 with new atypical active OT and 4 eyes with recurrent atypical OT were detected. Thirteen eyes with SRF were found in the macula and 12 involving the fovea.
Thirteen eyes with SRF associated with retinal necrosis, 3 eyes with CME, and 3 eyes with CNV were observed. Characteristics related to SRF were shown in Table 1. The mean maximum height of SRF was 161.0 (standard deviation (SD): 130.4, range: 23–478) μm. The mean total volume of SRF was 0.47 (SD: 0.91, range: 0.005–4.12) mm3. A total of 40.0% eyes had SRF smaller than 0.03 mm3 in volume.
Correlation of SRF with Retinal Necrosis
Thirteen eyes from 13 patients with SRF demonstrated evidence of retinal necrosis (Patients 1–13, Table 1, Fig 3), resulting in a prevalence of 33.3% (or 13/39) in all included eyes, or 39.4% (or 13/33) in eyes with typical active OT, or 65.0% (or 13/20) in eyes with SRF found in the study. All these eyes had lesions consistent with typical active OT, of which, 9 were located in the macula and 4 outside the macula but within posterior pole. All pockets of SRF were adjacent to the active necrotic lesions, except for one eye (Patient 13). At baseline, the mean maximum height of SRF was 147.8 (SD: 139.7, range: 33–478) μm with a mean total volume of SRF as 0.54 (SD: 1.10, range: 0.02–4.12) mm3. One patient was transferred to the local ophthalmologist without further follow-up in our clinic. For the remaining 12 eyes, SRF was observed with complete absorption after conventional anti-toxoplasmosis treatment during the study period. The mean duration for observation of SRF clearance was 33.8 (SD: 22.2, range: 7–84) days. The mean rate of SRF clearance was 0.0128 (SD: 0.0198, range: 0.0002–0.0665) mm3/day.
Parts A1-H1: fundus photos (FP) or infrared (IR) images of the macula overlying with early treatment diabetic retinopathy study (ETDRS) grid, for eyes with active OT. Red arrows in each eye indicated areas with active retinitis. Parts A2-H2: mean retinal thickness maps shown in the ETDRS grid corresponding to the overlapped grid in Figure A1-H1. Parts A3-H3: maps of mean SRF height shown in ETDRS grid corresponding to the overlapped grid in Figure A1-H1. 1 = superior outer macula; 2 = temporal outer macula; 3 = inferior outer macula; 4 = nasal outer macula; 5 = superior inner macula; 6 = temporal inner macula; 7 = inferior inner macula; 8 = nasal inner macula; 9 = central subfield.
Representative Case—Patient 9
A 23 year-old Caucasian woman, with a previous diagnosis of OT in the left eye, presented with new-onset “foggy vision” and pain in the left eye, in addition to persistent headache for a four-day period (Patient 9, Table 1, Fig 1). On presentation, VA was 20/20 in the left eye with 1+ vitreous cell. Dilated fundus examination revealed a normal macula and optic nerve head (ONH), but with evidence of whitish-yellow inflammatory lesion superior to the macula, in association with intraretinal hemorrhage and surrounding SRF. On OCT scanning though the fovea, vitreous cells were present without any retinal abnormality. On OCT scans through the active lesion, however, full thickness retinal interruption, which is corresponding to the retinal necrosis seen by fundus examination and greatly increased choroidal thickness were observed. SRF presented adjacent to the necrotic lesion, with a maximum height of 180 μm and a total volume of 0.84 mm3. The patient was commenced on oral clindamycin (300 mg 4 times daily) immediately and Prednisolone (75mg/d tapered) starting two days later.
After six weeks, the patient returned with a vision of 20/20 in the left eye. On fundus examination, the prior active lesion was noted to be smaller in size and without visible SRF. OCT scanning through the lesion showed no evidence of SRF, reduced numbers of vitreous cells, and decreased choroidal thickness compared to initial presentation.
Correlation of SRF with CME
A total of 3 eyes from 3 patients (Patients 14–16, Table 1) showed SRF in association with CME. Presence of SRF and CME (also with huge intraretinal cystoid lesion) superior to the macula adjacent to a typical active lesion was observed in Patient 14. Coexistence of SRF and CME in the macula, away from a typical active lesion in the peripheral retina was documented in Patient 15. SRF accompanied by CME in the macula in one eye with a previous diagnosis of OT without sign of uveitis activity in the current visit was seen in Patient 16. One eye (Patient 14) responded well to oral antibiotic treatment alone with complete absorption of SRF and CME (including the huge intraretinal cystoid lesion) seen after 25 days of therapy. However, two other eyes presented with long-standing CME with SRF lasting for months or years, despite conventional treatment and combined intravitreal injections (Patient 15 and16).
Representative Case—Patient 16
A 55 year-old Caucasian man presented on January 21 2011, with complaints of 'persistent decreased vision' in the left eye for a two-year period (Patient 16, Table 1, Fig 2). The patient was initially diagnosed with panuveitis secondary to OT in 1987 and had recurrences a number of times subsequently. The eye was complicated by cataract, epiretinal membrane (ERM) and CME, and has been treated with pars plana vitrectomy (PPV) with ERM peeling on November 29 2010 in a separate center. Forty-five days following vitrectomy, she also underwent cataract removal (phacoemulsification), intraocular lens implantation and release of posterior iris synechiae. However, she had no vision improvement afterwards.
On presentation to our clinic, VA was 20/320 in the left eye. Anterior examination of the left eye showed slight conjunctival hyperemia, a clear cornea with endothelial precipitates, a deep anterior chamber with Tyndall+, a round and responsive pupil, and the intraocular lens in proper position. Fundus examination revealed macular edema and a single old retinochoroidal scar in the superior nasal peripheral retina. SD-OCT demonstrated increased retinal thickness with CME and SRF(Table 1). On March 16, she was given oral acetazolamide 125 mg three times daily for 14 days. However, the CME and SRF remained unchanged 3 and 6 months after the initial visit. She was then given intravitreal injections of 1.25 mg Bevacizumab on 07.13.2011, 12.14.2011, and 03.06.2012, respectively. On 06.11.2012, she presented with a VA of 20/400 and complete absorption of SRF, however, with persistence of CME. She was then given an intravitreal injection of Dexamethasone implant 0.7mg on the same day. One month later, the CME had resolved on OCT, although without subjective vision improvement. However, CME recurred two months subsequently and she was given additional intravitreal injections of Dexamethasone implant on 09.10.2012, 01.28.2013, and 02.25.2013, respectively. During this time, CME was somewhat improved on one occasion (02.25.2013) but mainly remained unchanged till the end of the study period.
Correlation of SRF with CNV
Three eyes from 3 patients with SRF in association with CNV were found in our study (Patient 17–19, Table 1). SRF volume in Patient 17 was 0.005 mm3 at baseline and persisted in size till the last available visit (26 months after baseline). SRF in Patient 18 had a total volume of 0.49 mm3 at baseline and slowly decreased in amount until it completely resolved (31 months after baseline). SRF in Patient 19 presented with a total SRF volume of 0.19 mm3 at baseline and was resolved 8 months later. The patient had no further follow-up in our clinic.
SRF related to Other Manifestations
One eye presented with SRF unrelated to necrosis, CNV or CME (Patient 20, Table 1). The patient presented with 'neuritis' and was confirmed by laboratory testing (serology and aqueous humor analysis showed detection of intraocular Toxoplasma gondii antibodies with Goldmann/Witmer coefficient >3) to be atypical new active toxoplasmosis. SRF was detected superior to ONH, i.e. adjacent to the active lesion.
Discussion
In this study, the presence and clinical course of SRF in eyes with active OT were evaluated using SD-OCT. Out of 39 eyes (38 patients) included in the study, 20 eyes from 20 subjects demonstrated SRF in the posterior pole that was confirmed by SD-OCT. SRF was evident in 45.5% (or 15/33) of eyes with typical active OT and in 51.3% (or 20/39) of active OT in the current study. In total, 65.0% (or 13/20) of the cases with SRF were associated with retinal necrosis, 15.0% (or 3/20) with CME and 15.0% (or 3/20) with CNV.
Ocular toxoplasmosis classically appears as retinochoroidtitis, which is a focus of retinitis arising from the border of a retinochoroidal scar [21]. However, the phenotype can show considerable variation in atypical cases [21]. Knowledge of the various presentations of OT is important for the clinician and attention to the characteristics of OT may yield insights into disease mechanisms. In our study, "typical" OT was recognized and categorized based on the presence of active lesions of retinitis. One eye presented as neuritis without previous history of OT was defined as "new atypical active OT". Eyes with previous diagnosis of OT, which developed new symptoms without signs of active retinitis were referred as "recurrent atypical active OT" (e.g. CNV [22–26] and CME [1,12,21,22,27–30]), although a direct causative link cannot be made for sure.
SRF is seen by OCT as a hyporeflective space (i.e. detachment) between the neurosensory retina and the underlying RPE. Depending on the mechanism of SRF accumulation, RD has been classified into rhegmatogenous, tractional, and serous/exudative. Our study was intended to only describe cases with SRF associated with serous/exudative RD. The frequency of RD in OT was reported to be 5% or 6% by Friedmann, et al. and Bosch-Driessen, et.al, respectively [31, 8]. However, both reports only described tractional or rhegmatogenous RD in the study population, which made our study difficult to compare with their results. Some studies have mentioned SRF as a possible presentation of OT [5,6,9,10,31]. Until now, it has generally been thought that SRF is an uncommon feature of OT, and of many causes of serous detachment, OT is considered one of the least common [32].
Recent clinical observation and laboratory findings have led to a reassessment of many preconceived notions regarding OT.14 With the widespread availability of SD-OCT, SRF is now more frequently detected compared to the method with clinical observation alone or with stratus OCT [10]. Using SD-OCT, Diniz and colleagues observed SRF in 20% out of 10 eyes with active OT, which were overlooked by both Stratus OCT and clinical examination [10]. Foster et al. also reported the presence of SRF in 20.8% out of 24 eyes with active OT [33]. However, in these studies, the OCT scanning protocols covered a smaller area of the posterior pole. It is known that SRF in many lesions, especially those with small, is easily neglected if the OCT scanning is not performed close to the affected area. In our study, we could show that lesions with very little SRF (for example, total volume ≤ 0.3 mm3) were seen in the majority of cases. Thus, application of the OCT scanning through all involved areas in the posterior pole could possibly enhance the opportunity to detect SRF in our population. SRF was found in 45.5% of eyes with typical new active OT in our study, a presence much higher than expected based on the previous concept. Our results overall support the previous reports by Diniz et al. and Foster et al. that SRF is more commonly seen in active OT using SD-OCT. Yet, since many active OT lesions are in the peripheral retina, which is out of the reach of existing commercial OCT devices, our study using currently available SD-OCT systems still could not identify the true overall frequency of SRF or serous RD in OT. However, due to our extramacular OCT scanning protocol, the prevalence of SRF or serous RD in the posterior pole (or zone 1 plus zone 2) could be obtained reliably, at least in our cohort.
In eyes with typical (15 eyes) and new atypical (1 eye) active OT in our study population, the location of SRF is highly related to the site of active retinitis; only 2 eyes were noted to have SRF remote from the active lesion. This implies that the fluid accumulation in most cases was likely due to increased vascular permeability from the active inflammatory process of retinitis or retinal necrosis.
SRF related to retinal necrosis responded well to the anti-Toxoplasmosis treatment in our study: resolution of fluid was typically rapid after a short course of oral antibiotics with or without oral steroids. This process is independent of fluid volume, as resolution was observed even when the total volume of the SRF was relatively large (for example Patient 1). Although, for most of our patients, SRF was not the determining factor for vision recovery due to the central location of retinal necrosis; one would expect that when the necrosis doesn't involve the fovea, a vision improvement due to SRF should be seen after systemic anti-Toxoplasmosis therapy. On the other hand, SRF associated with CME demonstrated a different response to treatment. One eye with SRF and CME (including a large cystoid lesion) did respond favorably to systemic anti-toxoplasmosis therapy; however, two other eyes with long-standing SRF and CME did not improve despite combined convention and intravitreal treatment. Similarly for SRF related to CNV, the clearance of SRF appeared slow or incomplete. Although SRF in Patient 18 and 19 eventually resolved, this process took 936 days and 233 days, respectively. It is also not known whether Patient 19 had recurrence of CNV later on due to the loss of follow-up. For Patient 17, although the total volume of SRF was only 0.005 mm3 at baseline, it remained unchanged throughout the study period (2 years after the baseline).
Our study has many limitations that one would expect with a retrospective analysis. Although all OCT images were acquired according to a standard scanning protocol in our imaging unit, longitudinal assessment of fluid would best be accomplished with a prospective design with assessments and pre-specified standard intervals. Thus, our data must be interpreted with caution. Also, as discussed above, only a restricted area in the macula or posterior pole could be scanned thoroughly by our existing OCT system. Since many lesions with SRF could be missed without SD-OCT examination and OT may present with additional peripheral lesions, some areas with activity were possibly overlooked even though extramacular scanning protocol was utilized in our study.
Conclusion
In this study, we have observed that SRF or serous RD was much more commonly seen by SD-OCT in active OT, with a prevalence as 45.5% (or 15/33) in eyes with typical active OT or 51.3% (or 20/39) in eyes with all active OT. In eyes with typical and new atypical active OT, the location of SRF is highly related to the site of active retinitis, which implies that the fluid accumulation in most cases was likely due to increased vascular permeability from the active inflammatory process of retinitis or retinal necrosis. The majority of cases with SRF was associated with retinal necrosis and reacted well to the anti-toxoplasmosis therapy, regardless of baseline total fluid volume. However, SRF accompanying with CME or CNV responded less favorably or remained refractory to conventional or combined intravitreal treatment, even when the amount of SRF was small. Further studies are needed to verify its relevance.
Author Contributions
Conceived and designed the experiments: YO FL FMH UP. Performed the experiments: YO FL FMH QS. Analyzed the data: YO FL FMH QS. Contributed reagents/materials/analysis tools: SRS NS UP. Wrote the paper: YO FL PAK UP.
References
- 1. Bosch-Driessen LEH, Berendschot TTJM, Ongkosuwito JV, Rothova A (2002) Ocular toxoplasmosis: clinical features and prognosis of 154 patients. Ophthalmology 109: 869–878. pmid:11986090
- 2. Maenz M, Schlüter D, Liesenfeld O, Schares G, Gross U, Pleyer U (2014) Ocular Toxoplasmosis Past, present and new aspects of an old disease. Prog Retin Eye Res 39: 77–106. pmid:24412517
- 3. Dodds EM, Holland GN, Stanford MR, Yu F, Siu WO, Shah KH et al. (2008) Intraocular inflammation associated with ocular toxoplasmosis: relationships at initial examination. Am J Ophthalmol 146: 856–65.e2. pmid:19027421
- 4. Lehpamer B, Moshier E, Goldberg N, Ackert J, Godbold J, Jabs DA (2013) Subretinal fluid in uveitic macular edema: effect on vision and response to therapy. Am J Ophthalmol 155: 143–149. pmid:23022159
- 5. Matsubayashi H, Koike T, Uyemura M, Sohy , Hamano K (1961) A case of ocular toxoplasmosis in an adult, the infection being confirmed by the isolation of the parasite from subretinal fluid. Keio J Med 10: 209–224. pmid:14471249
- 6. Lieb DF, Scott IU, Flynn HW, Davis JL, Demming SM (2004) Acute acquired toxoplasma retinitis may present similarly to unilateral acute idiopathic maculopathy. Am J Ophthalmol 137: 940–942. pmid:15126165
- 7. Oréfice JL, Costa RA, Oréfice F, Campos W, da Costa-Lima D, Scott IU (2007) Vitreoretinal morphology in active ocular toxoplasmosis: a prospective study by optical coherence tomography. Br J Ophthalmol 91: 773–780. pmid:17135336
- 8. Bosch-Driessen LH, Karimi S, Stilma JS, Rothova A (2000) Retinal detachment in ocular toxoplasmosis. Ophthalmology 107: 36–40. pmid:10647716
- 9. Willerson D, Aaberg TM, Reeser F, Meredith TA (1977) Unusual ocular presentation of acute toxoplasmosis. Br J Ophthalmol 61: 693–698. pmid:588525
- 10. Diniz B, Regatieri C, Andrade R, Maia A (2011) Evaluation of spectral domain and time domain optical coherence tomography findings in toxoplasmic retinochoroiditis. Clin Ophthalmol 5: 645–650. pmid:21629569
- 11. Regatieri CV, Alwassia A, Zhang JY, Vora R, Duker JS (2012) Use of optical coherence tomography in the diagnosis and management of uveitis. Int Ophthalmol Clin 52: 33–43. pmid:22954927
- 12. Ouyang Y, Pleyer U, Shao Q, Keane PA, Stübiger N, Joussen AM, et al. (2014) Evaluation of cystoid change phenotypes in ocular toxoplasmosis using optical coherence tomography. PLoS One 9: e86626. pmid:24505261
- 13. Keane PA, Patel PJ, Liakopoulos S, Heussen FM, Sadda SR, Tufail A (2012) Evaluation of age-related macular degeneration with optical coherence tomography. Surv Ophthalmol 57: 389–414. pmid:22898648
- 14.
Dodds E (n.d.) (1999) Ocular toxoplasmosis: Clinical presentation, diagnosis and therapy. in: Focal Points: Clinical Modules for Ophthalmologists. v. XVII. San Francisco: American Academy of Ophthalmology.
- 15. Garweg JG, de Groot-Mijnes JDF, Montoya JG (2011) Diagnostic approach to ocular toxoplasmosis. Ocul Immunol Inflamm 19: 255–261. pmid:21770803
- 16. Holland GN, Buhles WC, Mastre B, Kaplan HJ (1989) A controlled retrospective study of ganciclovir treatment for cytomegalovirus retinopathy. Use of a standardized system for the assessment of disease outcome. UCLA CMV Retinopathy. Study Group. Arch Ophthalmol 107: 1759–1766. pmid:2556989
- 17. Keane PA, Allie M, Turner SJ, Southworth HS, Sadda SR, Murray PI, et al. (2013) Characterization of birdshot chorioretinopathy using extramacular enhanced depth optical coherence tomography. JAMA Ophthalmol 131: 341–350. pmid:23307137
- 18. Ouyang Y, Heussen FM, Mokwa N, Walsh AC, Durbin MK, Keane PA, et al. (2011) Spatial distribution of posterior pole choroidal thickness by spectral domain optical coherence tomography. Invest Ophthalmol Vis Sci 52: 7019–7026. pmid:21810980
- 19. Ouyang Y, Heussen FM, Keane PA, Sadda SR, Walsh AC (2013) The retinal disease screening study: prospective comparison of nonmydriatic fundus photography and optical coherence tomography for detection of retinal irregularities. Invest Ophthalmol Vis Sci 54: 1460–1468. pmid:23322579
- 20. Ouyang Y, Heussen FM, Keane PA, Sadda SR, Walsh AC (2013) The retinal disease screening study: retrospective comparison of nonmydriatic fundus photography and three-dimensional optical coherence tomography for detection of retinal irregularities. Invest Ophthalmol Vis Sci 54: 5694–5700. pmid:23847317
- 21. Holland GN (2004) Ocular toxoplasmosis: a global reassessment. Part II: disease manifestations and management. Am J Ophthalmol 137: 1–17. pmid:14700638
- 22. Delair E, Latkany P, Noble AG, Rabiah P, McLeod R, Brézin A (2011) Clinical manifestations of ocular toxoplasmosis. Ocul Immunol Inflamm 19: 91–102. pmid:21428746
- 23. Atmaca LS, Simsek T, Atmaca Sonmez P, Sonmez K (2006) Fluorescein and indocyanine green angiography in ocular toxoplasmosis. Graefes Arch Clin Exp Ophthalmol 244: 1688–1691. pmid:16673136
- 24. Garza-Leon M, Garcia LA (2012) Ocular toxoplasmosis: clinical characteristics in pediatric patients. Ocul Immunol Inflamm 20: 130–138. pmid:22409567
- 25. Kovačević-Pavićević D, Radosavljević A, Ilić A, Kovačević I, Djurković-Djaković O (2012) Clinical pattern of ocular toxoplasmosis treated in a referral centre in Serbia. Eye (Lond) 26: 723–728. pmid:22361847
- 26. Wirthlin R, Song A, Song J, Rosenfeld PJ (2006) Verteporfin photodynamic therapy of choroidal neovascularization secondary to ocular toxoplasmosis. Arch Ophthalmol 124: 741–743. pmid:16682600
- 27. Smith JR, Cunningham ET (2002) Atypical presentations of ocular toxoplasmosis. Curr Opin Ophthalmol 13: 387–392. pmid:12441842
- 28. Kianersi F, Naderi Beni A, Naderi Beni Z (2012) Clinical manifestation and prognosis of active ocular toxoplasmosis in Iran. Int Ophthalmol 32: 539–545. pmid:22733253
- 29. Bonfioli AA, Orefice F (2005) Toxoplasmosis. Semin Ophthalmol 20: 129–141. pmid:16282146
- 30. Schlaegel TF, Weber JC (1984) The macula in ocular toxoplasmosis. Arch Ophthalmol 102: 697–698. pmid:6721755
- 31. Friedmann CT, Knox DL (1969) Variations in recurrent active toxoplasmic retinochoroiditis. Arch Ophthalmol 81: 481–493. pmid:5777756
- 32. Kraushar MF, Gluck SB, Pass S (1979) Toxoplasmic retinochoroiditis presenting as serous detachment of the macula. Ann Ophthalmol 11: 1513–1514. pmid:555845
- 33.
Foster CS, Vitale AT (2013) Diagnosis and Treatment of Uveitis. JP Medical Ltd.